瑞莎珠单抗对克罗恩病患者健康相关生活质量的影响:3期MOTIVATE、ADVANCE和FORTIFY临床试验结果
分析ADVANCE(N=850)和MOTIVATE(N=569)12周诱导试验及FORTIFY(N=462)52周维持试验数据,评估瑞莎珠单抗对克罗恩病患者健康相关生活质量的影响。瑞莎珠单抗600或1200 mg静脉诱导治疗在12周时使更多患者达到IBDQ和FACIT-F应答,且这些改善在52周维持治疗(180或360 mg皮下)后持续存在。
要点
- 12周时瑞莎珠单抗600或1200 mg组IBDQ应答率高于安慰剂组。
- 12周时瑞莎珠单抗组FACIT-F应答率高于安慰剂组。
- 52周维持治疗期间上述改善持续存在。
核心结论
- 瑞莎珠单抗600或1200 mg静脉诱导治疗使中重度克罗恩病患者疾病特异性和一般患者报告结局(包括疲劳)获得有临床意义的改善。
- 这些改善在瑞莎珠单抗180或360 mg皮下维持治疗52周后持续存在。
研究设计与样本
- 分析12周诱导试验ADVANCE(N=850)和MOTIVATE(N=569),比较瑞莎珠单抗600 mg或1200 mg静脉给药与安慰剂静脉给药。
- 分析52周维持试验FORTIFY(N=462),比较瑞莎珠单抗180或360 mg皮下给药与安慰剂皮下给药。
- 评估指标包括炎症性肠病问卷(IBDQ)、慢性病治疗功能评估-疲劳(FACIT-F)、36项简表健康调查(SF-36)、EuroQol五维五水平量表(EQ-5D-5L)和工作生产力。
- 在第12周和第52周确定所有结局的平均变化和达到临床有意义改善的患者百分比。
主要发现
- 第12周ADVANCE试验中,瑞莎珠单抗600 mg组、1200 mg组和安慰剂组分别有70.2%、75.5%和47.8%的患者达到IBDQ应答(p ≤ 0.001)。
- 第12周MOTIVATE试验中,瑞莎珠单抗600 mg组、1200 mg组和安慰剂组分别有61.7%、68.5%和48.2%的患者达到IBDQ应答(p ≤ 0.01)。
- 第12周ADVANCE试验中,瑞莎珠单抗600 mg组、1200 mg组和安慰剂组分别有51.3%、48.0%和35.7%的患者达到FACIT-F应答(p ≤ 0.01)。
- 第12周MOTIVATE试验中,瑞莎珠单抗600 mg组、1200 mg组和安慰剂组分别有44.2%、49.1%和33.7%的患者达到FACIT-F应答(p < 0.05)。
- SF-36躯体成分和心理成分汇总评分、EQ-5D-5L及工作生产力指标中的活动受损方面观察到相似趋势。
关键数值与推荐
- IBDQ应答:ADVANCE试验瑞莎珠单抗600 mg组70.2%、1200 mg组75.5% vs 安慰剂组47.8%(p ≤ 0.001)。
- IBDQ应答:MOTIVATE试验瑞莎珠单抗600 mg组61.7%、1200 mg组68.5% vs 安慰剂组48.2%(p ≤ 0.01)。
- FACIT-F应答:ADVANCE试验瑞莎珠单抗600 mg组51.3%、1200 mg组48.0% vs 安慰剂组35.7%(p ≤ 0.01)。
- FACIT-F应答:MOTIVATE试验瑞莎珠单抗600 mg组44.2%、1200 mg组49.1% vs 安慰剂组33.7%(p < 0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Crohn's disease has a substantial negative impact on health-related quality of life (HRQoL). AIM: To examine the effects of risankizumab on HRQoL in Crohn's disease METHODS: We analysed data from patients with Crohn's disease from 12-week induction trials ADVANCE (N = 850) and MOTIVATE (N = 569) with risankizumab 600 mg or 1200 mg intravenous (IV) versus placebo IV and a 52-week maintenance trial FORTIFY (N = 462) with risankizumab 180 or 360 mg subcutaneous (SC) versus placebo SC. Outcomes included Inflammatory Bowel Disease Questionnaire (IBDQ), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), 36-item Short Form Health Survey (SF-36), EuroQol 5-Dimension-5-Level (EQ-5D-5L) and work productivity. The mean change and percentages of patients achieving clinically meaningful improvement in all outcomes were determined at weeks 12 and 52. RESULTS: At week 12, more patients in the risankizumab 600 or 1200 mg groups achieved IBDQ response than with placebo (ADVANCE: 70.2%, 75.5% vs. 47.8%, p ≤ 0.001; MOTIVATE: 61.7%, 68.5% vs. 48.2%, p ≤ 0.01) and FACIT-F response (ADVANCE: 51.3%, 48.0% vs. 35.7%, p ≤ 0.01; MOTIVATE: 44.2%, 49.1% vs. 33.7%, p < 0.05). These improvements persisted at week 52 with risankizumab maintenance treatment. Similar trends were observed for SF-36 physical and mental component summary scores, EQ-5D-5L and activity impairment within work productivity measures. CONCLUSIONS: Risankizumab induction therapy (600 or 1200 mg IV) led to clinically meaningful improvements in disease-specific and general patient-reported outcomes, including fatigue, in patients with moderate to severe Crohn's disease. These improvements were sustained after 52 weeks of risankizumab (180 or 360 mg SC) maintenance therapy.
引用
- Peyrin-Biroulet L, Ghosh S, Lee SD, et al. Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials. Aliment Pharmacol Ther. 2022. PMID: 36266762. doi:10.1111/apt.17242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。